RATIONALE & OBJECTIVE: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) examined in the ongoing phase 2 DUET trial for focal segmental glomerulosclerosis (FSGS). In the DUET 8-week double-blind period, sparsentan resulted in greater proteinuria reduction versus irbesartan. We report the long-term efficacy and safety of sparsentan during the open-label extension over more than 4 years. STUDY DESIGN: Patients were examined from their first sparsentan dose (double-blind period or open-label extension) through 4.6 years. SETTING & PARTICIPANTS: Patients with FSGS, excluding secondary FSGS. INTERVENTION: Sparsentan (200, 400, and 800 mg/d). OUTCOMES: Urinary protein-creatinine ratio, FSGS partial remission endpoint (urinary protein-creatinine ratio ≤1.5 g/g and >40% reduction from baseline), estimated glomerular filtration rate, and blood pressure approximately every 12 weeks. Treatment-emergent adverse events by year and cases/100 patient-years. RESULTS: 109 patients were enrolled; 108 received ≥1 sparsentan dose; 103 entered the open-label extension (68 sparsentan, 35 irbesartan during the double-blind period). Sparsentan was ongoing in 45/108 patients (41.7%); median time to treatment discontinuation was 3.9 years (95% CI, 2.6-5.2). Mean percent proteinuria reduction from baseline was sustained through follow-up. Achieving partial remission within 9 months of first sparsentan dose (52.8% of patients) versus not achieving (47.2%) was associated with significantly slower rate of estimated glomerular filtration rate decline over the entire treatment period (-2.70 vs -6.56; P = 0.03) and in the first 2 years (-1.69 vs -6.46; P = 0.03). The most common treatment-emergent adverse events (>9 cases/100 patient-years) were headache, peripheral edema, upper respiratory infection, hyperkalemia, and hypotension. Peripheral edema and hypotension declined from year 1 (13.9% and 15.7% of patients, respectively) to ≤4% in years ≥2. There were no cases of heart failure and no patient deaths. LIMITATIONS: The open-label extension does not include a comparison group. CONCLUSIONS: Long-term sparsentan treatment showed sustained proteinuria reduction and a consistent safety profile.

There is substantial unmet clinical need for safe and effective treatments for focal segmental glomerulosclerosis (FSGS), a kidney lesion with varied causes. Sparsentan is being studied for treatment of FSGS and targets 2 important pathways (endothelin-1 and angiotensin II) that lead to the loss of kidney function. In the 8-week randomized, double-blind DUET study in patients with FSGS, sparsentan reduced the amount of protein in the urine better than irbesartan (a blood pressure medicine often used to treat FSGS). We examined long-term treatment with sparsentan over >4 years in the DUET open-label extension. We found sustained proteinuria reduction in patients who continued treatment with sparsentan and a consistent safety profile with no new or unexpected adverse effects.

Charles University General University Hospital Prague Czech Republic

Children's Mercy Hospital Kansas City MO

Icahn School of Medicine at Mount Sinai New York NY

Travere Therapeutics Inc San Diego CA

University of Bari Aldo Moro Bari Italy

University of Michigan Ann Arbor MI

University of Minnesota Medical School Minneapolis MN

Kidney Med. 2024 May 22;6(6):100844. doi: 10.1016/j.xkme.2024.100844. PubMed

See more in PubMed

D’Agati V.D., Kaskel F.J., Falk R.J. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–2411. doi: 10.1056/NEJMra1106556. PubMed DOI

De Vriese A.S., Wetzels J.F., Glassock R.J., Sethi S., Fervenza F.C. Therapeutic trials in adult FSGS: lessons learned and the road forward. Nat Rev Nephrol. 2021;17(9):619–630. doi: 10.1038/s41581-021-00427-1. PubMed DOI PMC

Saran R., Li Y., Robinson B., et al. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2016;67(3 suppl 1):S1–S390. PubMed PMC

Spino C., Jahnke J.S., Selewski D.T., Massengill S., Troost J., Gipson D.S. Changing the paradigm for the treatment and development of new therapies for FSGS. Front Pediatr. 2016;4:25. doi: 10.3389/fped.2016.00025. PubMed DOI PMC

Trachtman R., Sran S.S., Trachtman H. Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatr Nephrol. 2015;30(10):1793–1802. doi: 10.1007/s00467-015-3062-1. PubMed DOI

Uffing A., Pérez-Sáez M.J., Mazzali M., et al. Recurrence of FSGS after kidney transplantation in adults. Clin J Am Soc Nephrol. 2020;15(2):247–256. doi: 10.2215/CJN.08970719. PubMed DOI PMC

Wood E.L., Kwan L., Burrows J.E., Singh G., Veale J., Lum E.L. Early recurrence of focal segmental glomerulosclerosis in kidney transplant recipients: when to consider regifting. Transpl Rep. 2023;8(2) doi: 10.1016/j.tpr.2023.100130. DOI

Reiser J., Nast C.C., Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014;21(5):417–421. doi: 10.1053/j.ackd.2014.05.010. PubMed DOI PMC

Rosenberg A.Z., Kopp J.B. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502–517. doi: 10.2215/CJN.05960616. PubMed DOI PMC

Sadowski C.E., Lovric S., Ashraf S., et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2015;26(6):1279–1289. doi: 10.1681/ASN.2014050489. PubMed DOI PMC

Hildebrandt F. Decade in review—genetics of kidney diseases: genetic dissection of kidney disorders. Nat Rev Nephrol. 2015;11(11):635–636. doi: 10.1038/nrneph.2015.148. PubMed DOI PMC

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1–S276. doi: 10.1016/j.kint.2021.05.021. PubMed DOI

Sethna C.B., Gipson D.S. Treatment of FSGS in children. Adv Chronic Kidney Dis. 2014;21(2):194–199. doi: 10.1053/j.ackd.2014.01.010. PubMed DOI

Kohan D.E., Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014;86(5):896–904. doi: 10.1038/ki.2014.143. PubMed DOI PMC

Smeijer J.D., Kohan D.E., Webb D.J., Dhaun N., Heerspink H.J.L. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease. Curr Opin Nephrol Hypertens. 2021;30(4):456–465. doi: 10.1097/MNH.0000000000000716. PubMed DOI

Komers R., Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877–R884. doi: 10.1152/ajpregu.00425.2015. PubMed DOI PMC

Trachtman H., Hogan J.J., Tesar V., Komers R. Sparsentan. dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy. Drugs Future. 2020;45(2):79–98. doi: 10.1358/dof.2020.45.2.3058863. DOI

Benigni A., Buelli S., Kohan D.E. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatr Nephrol. 2021;36(4):763–775. doi: 10.1007/s00467-020-04518-2. PubMed DOI

Heerspink H.J.L., Parving H.H., Andress D.L., et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393(10184):1937–1947. doi: 10.1016/S0140-6736(19)30772-X. PubMed DOI

de Zeeuw D., Coll B., Andress D., et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083–1093. doi: 10.1681/ASN.2013080830. PubMed DOI PMC

Dhaun N., MacIntyre I.M., Kerr D., et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57(4):772–779. doi: 10.1161/HYPERTENSIONAHA.110.167486. PubMed DOI

Trachtman H., Nelson P., Adler S., et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745–2754. doi: 10.1681/ASN.2018010091. PubMed DOI PMC

Komers R., Gipson D.S., Nelson P., et al. Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET) Kidney Int Rep. 2017;2(4):654–664. doi: 10.1016/j.ekir.2017.02.019. PubMed DOI PMC

Troost J.P., Trachtman H., Nachman P.H., et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2018;13(3):414–421. doi: 10.2215/CJN.04780517. PubMed DOI PMC

Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–470. doi: 10.7326/0003-4819-130-6-199903160-00002. PubMed DOI

Levey A.S., Coresh J., Greene T., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254. doi: 10.7326/0003-4819-145-4-200608150-00004. PubMed DOI

Schwartz G.J., Work D.F. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4(11):1832–1843. doi: 10.2215/CJN.01640309. PubMed DOI

Trachtman H., Diva U., Murphy E., Wang K., Inrig J., Komers R. Implications of complete proteinuria remission at any time in focal segmental glomerulosclerosis: sparsentan DUET trial. Kidney Int Rep. 2023;8(10):2017–2028. doi: 10.1016/j.ekir.2023.07.022. PubMed DOI PMC

Gyarmati G., Shroff U., Izuhara A., Komers R., Bedard P., Peti-Peterdi J. FC 016 sparsentan improves glomerular blood flow and augments protective tissue remodeling in mouse models of focal segmental glomerulosclerosis (FSGS) Nephrol Dial Transplant. 2021;36(suppl 1)

Gyarmati G., Deepak S.K., Shroff U.N., et al. Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis (FSGS) [abstract] J Am Soc Nephrol. 2022;33:FR–OR56.

Bedard P., Jenkinson C., Komers R. MO255: Sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis (FSGS) [abstract] Nephrol Dial Transplant. 2022;37(suppl 3) doi: 10.1093/ndt/gfac067.054. DOI

Nagasawa H., Suzuki H., Jenkinson C., et al. MO261: Sparsentan, the dual endothelin angiotensin receptor antagonist (DEARA), attenuates albuminuria and protects from the development of renal injury to a greater extent than losartan in the GDDY mouse model of IgA nephropathy: a 16-week study [abstract] Nephrol Dial Transplant. 2022;37(suppl 3) doi: 10.1093/ndt/gfac067.060. DOI

Reily C., Moldoveanu Z., Pramparo T., et al. The dual endothelin angiotensin receptor antagonist (DEARA) sparsentan protects from glomerular hypercellularity and associated immune/inflammatory gene network activity in a model of IgA nephropathy. J Am Soc Nephrol. 2021;32:459. [abstract] PubMed

Jenkinson C., Moldoveanu Z., Komers R., et al. SAT-010 protective effects of sparsentan from proliferative glomerular injury induced by administration of human immune complexes in a murine model of experimental IgA nephropathy. Kidney Int Rep. 2019;4(7):S5–S6.

Cosgrove D., Gratton M.A., Madison J., et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J Pathol. 2023;260(3):353–364. doi: 10.1002/path.6087. PubMed DOI PMC

Troyanov S., Wall C.A., Miller J.A., Scholey J.W., Cattran D.C. Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061–1068. doi: 10.1681/ASN.2004070593. PubMed DOI

Troost J.P., Trachtman H., Spino C., et al. Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis. Am J Kidney Dis. 2021;77(2):216–225. doi: 10.1053/j.ajkd.2020.04.014. PubMed DOI PMC

Gipson D.S., Troost J.P., Spino C., et al. Comparing kidney health outcomes in children, adolescents, and adults with focal segmental glomerulosclerosis. JAMA Netw Open. 2022;5(8) doi: 10.1001/jamanetworkopen.2022.28701. PubMed DOI PMC

Mann J.F., Green D., Jamerson K., et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527–535. doi: 10.1681/ASN.2009060593. PubMed DOI PMC

Kohan D.E., Pritchett Y., Molitch M., et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):763–772. doi: 10.1681/ASN.2010080869. PubMed DOI PMC

Murugesan N., Gu Z., Fadnis L., et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005;48(1):171–179. doi: 10.1021/jm049548x. PubMed DOI

Heerspink H.J.L., Radhakrishnan J., Alpers C.E., et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584–1594. doi: 10.1016/S0140-6736(23)00569-X. PubMed DOI

Travere Therapeutics announces topline results from two-year primary efficacy endpoint in pivotal phase 3 DUPLEX study of sparsentan in focal segmental glomerulosclerosis. Travere Therapeutics, Inc.; Published May 1, 2023. https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-topline-results-two-year-primary

Rheault M.N., Alpers C.E., Barratt J., et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Engl J Med. 2023;389(26):2436–2445. doi: 10.1056/NEJMoa2308550. PubMed DOI

Rovin B.H., Barratt J., Heerspink H.J.L., et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077–2090. doi: 10.1016/S0140-6736(23)02302-4. PubMed DOI